Amgen Inc. (AMGN)
Why Amgen (AMGN) Dipped More Than Broader Market Today
Amgen (AMGN) closed the most recent trading day at $305.02, moving -0.22% from the previous trading session.
Is Trending Stock Amgen Inc. (AMGN) a Buy Now?
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
A Simple $1 Million Passive Income Portfolio For Retirement
Warren Buffett once opined on how to live off of dividends in retirement. We discuss a simple way to follow his advice on this. We also share how to further enhance the yield on this portfolio while still generating strong dividend growth and keeping risk low.
Amgen's (AMGN) Uplizna Meets Study Goal for Rare Disease
Data from a late-stage study shows that treatment with Amgen's (AMGN) Uplizna achieves a statistically significant reduction in the risk of flares in patients with IgG4-RD, a rare disease.
Amgen's drug meets main goal in late-stage study for rare disease
Amgen said on Wednesday its drug to treat patients with an immune system-related condition has met the main goal of a late-stage study.
Amgen Is A Fantastic Dividend Growth Stock With A Weight-Loss Wild Card
The obesity market is expected to reach $130 billion by 2030, benefiting companies like Eli Lilly and Novo Nordisk. Amgen, a biotech company, is experiencing innovation-fueled growth with impressive new products and international expansion. Amgen offers shareholder value with a strong financial performance, dividend hikes, and a favorable valuation.
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
Eli Lilly and Novo Nordisk aren't the only ones making anti-obesity drugs. Amgen, AstraZeneca, and Viking Therapeutics have credible candidates.
Where Will Amgen Be in 3 Years?
Amgen has some compelling late-stage programs in its pipeline. Growth is likely to accelerate as the biotech makes progress.
Amgen's rare-disease treatment biosimilar Bkemv gets FDA approval
Pharmaceutical regulators approved Amgen's AMGN, -1.85% Bkemv, a biosimilar to rare-disease treatment Soliris.
US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment
The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood disorder treatment Soliris.
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Amgen's Catching Up to Novo Nordisk and Eli Lilly. Should You Buy It?
Amgen has a promising entrant in the anti-obesity therapies space. Its candidate is in phase 2 trials, but there are already plans for phase 3.
